A Phase I Trial of Intracavitary Doxorubicin (Adriamycin) Alternating with Cisplatin

摘要: A substantial pharmacologic advantage might be gained by delivering chemotherapy directly into the peritoneum or pleura for tumors confined to these serous cavities. Peak drug levels in ascites after intraperitoneal administration range from 30 W times that achieved plasma intravenous (IV) dosage. (Table 1) If a has high level of hepatic extraction, concentration intracavitary (IC) given dose may substantially lower than IV administration.